MX2009002091A - Metodos para reducir las concentraciones de glucosa. - Google Patents
Metodos para reducir las concentraciones de glucosa.Info
- Publication number
- MX2009002091A MX2009002091A MX2009002091A MX2009002091A MX2009002091A MX 2009002091 A MX2009002091 A MX 2009002091A MX 2009002091 A MX2009002091 A MX 2009002091A MX 2009002091 A MX2009002091 A MX 2009002091A MX 2009002091 A MX2009002091 A MX 2009002091A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- glucose levels
- lowering glucose
- patient
- lowering
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract 3
- 239000008103 glucose Substances 0.000 title abstract 3
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 abstract 1
- 229960003401 ramipril Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84085006P | 2006-08-28 | 2006-08-28 | |
| PCT/EP2007/007160 WO2008025450A1 (en) | 2006-08-28 | 2007-08-14 | Methods of lowering glucose levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009002091A true MX2009002091A (es) | 2009-03-09 |
Family
ID=38578487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009002091A MX2009002091A (es) | 2006-08-28 | 2007-08-14 | Metodos para reducir las concentraciones de glucosa. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080188538A1 (enExample) |
| EP (1) | EP2059242A1 (enExample) |
| JP (1) | JP2010501604A (enExample) |
| KR (1) | KR20090042976A (enExample) |
| CN (1) | CN101573110A (enExample) |
| AU (1) | AU2007291602B2 (enExample) |
| BR (1) | BRPI0716411A2 (enExample) |
| CA (1) | CA2661598A1 (enExample) |
| IL (1) | IL197189A0 (enExample) |
| MX (1) | MX2009002091A (enExample) |
| NO (1) | NO20090926L (enExample) |
| WO (1) | WO2008025450A1 (enExample) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
| DE3226768A1 (de) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| DE3413710A1 (de) * | 1984-04-12 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur behandlung der herzinsuffizienz |
| DE3739690A1 (de) * | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
| CA2026686A1 (en) * | 1989-10-30 | 1991-05-01 | Werner Tschollar | Method for preventing onset of type ii diabetes employing an ace inhibitor |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| DK1216038T3 (da) * | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
| WO2003032965A2 (en) * | 2001-10-17 | 2003-04-24 | King Pharmaceuticals Research And Development, Inc | Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
| US20050065203A1 (en) * | 2001-10-17 | 2005-03-24 | Salim Yusuf | Method of reducing type 2 diabetes in high risk patients |
| CA2458288A1 (en) * | 2003-03-11 | 2004-09-11 | Institut De Cardiologie De Montreal / Montreal Heart Institute | Method and compound to reduce the incidence of diabetes in a subject with chronic heart failure |
-
2007
- 2007-08-14 CA CA002661598A patent/CA2661598A1/en not_active Abandoned
- 2007-08-14 EP EP07786675A patent/EP2059242A1/en not_active Withdrawn
- 2007-08-14 KR KR1020097005581A patent/KR20090042976A/ko not_active Ceased
- 2007-08-14 WO PCT/EP2007/007160 patent/WO2008025450A1/en not_active Ceased
- 2007-08-14 BR BRPI0716411-4A2A patent/BRPI0716411A2/pt not_active IP Right Cessation
- 2007-08-14 MX MX2009002091A patent/MX2009002091A/es not_active Application Discontinuation
- 2007-08-14 AU AU2007291602A patent/AU2007291602B2/en not_active Ceased
- 2007-08-14 JP JP2009525948A patent/JP2010501604A/ja active Pending
- 2007-08-14 CN CNA2007800400375A patent/CN101573110A/zh active Pending
- 2007-08-28 US US11/846,310 patent/US20080188538A1/en not_active Abandoned
-
2009
- 2009-02-23 IL IL197189A patent/IL197189A0/en unknown
- 2009-02-27 NO NO20090926A patent/NO20090926L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL197189A0 (en) | 2009-12-24 |
| JP2010501604A (ja) | 2010-01-21 |
| AU2007291602A1 (en) | 2008-03-06 |
| CA2661598A1 (en) | 2008-03-06 |
| AU2007291602B2 (en) | 2012-09-06 |
| US20080188538A1 (en) | 2008-08-07 |
| EP2059242A1 (en) | 2009-05-20 |
| CN101573110A (zh) | 2009-11-04 |
| KR20090042976A (ko) | 2009-05-04 |
| WO2008025450A1 (en) | 2008-03-06 |
| NO20090926L (no) | 2009-03-27 |
| BRPI0716411A2 (pt) | 2013-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112320T1 (el) | Τιτλοδοτηση της ταπενταδολης | |
| ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
| MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
| EA201170465A1 (ru) | Способы лечения прогрессирующего множественного склероза | |
| IL185808A0 (en) | Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments | |
| WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
| EA201170753A1 (ru) | Налмефена гидрохлорид дигидрат | |
| MX2009009416A (es) | Derivados de bencimidazol y sus metodos de uso. | |
| MY151048A (en) | Use of flibanserin for the treatment of post-menopausal sexual desire disorders | |
| UA102432C2 (ru) | Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y | |
| MY153408A (en) | Novel methods | |
| UA107204C2 (uk) | Протигрибкова композиція, що містить грибковий організм pythium oligandrum | |
| EP1962839A4 (en) | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER | |
| WO2009074247A8 (de) | Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel | |
| MX2011008994A (es) | Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2. | |
| TW200740429A (en) | Methods and dosage forms for reducing side effects of carbamate compounds | |
| NZ595364A (en) | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION | |
| NZ597866A (en) | Therapeutic lactams | |
| WO2007130501A3 (en) | Combination therapy for treatment of cancer | |
| WO2010004031A3 (en) | Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist | |
| MX2011009804A (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. | |
| IL185807A0 (en) | Use of amino-substituted benzimidazoles | |
| WO2007095609A3 (en) | Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder | |
| WO2009074498A8 (en) | Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate | |
| MY154376A (en) | A transdermal fluid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |